Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer

The Pharmacogenomics Journal volume 11, pages 437–443 (2011)Cite this article

Subjects

Abstract

Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals and cannot be determined before the final pathologic evaluation. The aim of this study was to identify germline genetic markers that could predict sensitivity or resistance to preoperative radiochemotherapy (RT-CT) in rectal cancer. We evaluated the predictive value of 128 single-nucleotide polymorphisms (SNPs) in 71 patients preoperatively treated by RT-CT. The selected SNPs were distributed over 76 genes that are involved in various cellular processes such as DNA repair, apoptosis, proliferation or immune response. The SNPs superoxide dismutase 2 (SOD2) rs4880 (P=0.005) and interleukin-13 (IL13) rs1800925 (P=0.0008) were significantly associated with tumor response to chemoradiation. These results reinforce the idea of using germline polymorphisms for personalized treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740.

    Article  CAS  Google Scholar 

  2. Sauer R . Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res 2002; 8: 7–17.

    Article  CAS  Google Scholar 

  3. Crane CH, Skibber JM, Feig BW, Vauthey J, Thames HD, Curley SA et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 2003; 97: 517–524.

    Article  Google Scholar 

  4. Gerard J, Chapet O, Nemoz C, Hartweig J, Romestaing P, Coquard R et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404–2409.

    Article  Google Scholar 

  5. Ruo L, Tickoo S, Klimstra D, Minsky B, Saltz L, Mazumdar M et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236: 75–81.

    Article  Google Scholar 

  6. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688–8696.

    Article  Google Scholar 

  7. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99–107.

    Article  Google Scholar 

  8. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ . Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 2006; 32: 55–64.

    Article  CAS  Google Scholar 

  9. Kuremsky JG, Tepper JE, McLeod HL . Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009; 74: 673–688.

    Article  CAS  Google Scholar 

  10. Spindler KG, Nielsen JN, Lindebjerg J, Jakobsen A . Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 2007; 50: 1363–1369.

    Article  Google Scholar 

  11. Grube D . Constants and variables in immunohistochemistry. Arch Histol Cytol 2004; 67: 115–134.

    Article  CAS  Google Scholar 

  12. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789–796.

    Article  Google Scholar 

  13. Ulrich CM, Robien K, McLeod HL . Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912–920.

    Article  CAS  Google Scholar 

  14. Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J . Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005; 54: 171–196.

    Article  Google Scholar 

  15. Dworak O, Keilholz L, Hoffmann A . Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19–23.

    Article  CAS  Google Scholar 

  16. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006; 34: D617–D621.

    Article  CAS  Google Scholar 

  17. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644–645.

    PubMed  Google Scholar 

  18. Storey JD, Tibshirani R . Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440–9445.

    Article  CAS  Google Scholar 

  19. Wright S . Adjusted p-values for simultaneous inference. Biometrics 1992; 48: 1005–1013.

    Article  Google Scholar 

  20. Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007; 297: 489–498.

    Article  CAS  Google Scholar 

  21. Oberley LW . Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 2005; 59: 143–148.

    Article  CAS  Google Scholar 

  22. Wang CY, Mayo MW, Baldwin AS . TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784–787.

    Article  CAS  Google Scholar 

  23. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA . Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003; 22: 5813–5827.

    Article  CAS  Google Scholar 

  24. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y . Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson′s disease. Biochem Biophys Res Commun 1996; 226: 561–565.

    Article  CAS  Google Scholar 

  25. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005; 15: 311–319.

    Article  CAS  Google Scholar 

  26. Terabe M, Park JM, Berzofsky JA . Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004; 53: 79–85.

    Article  CAS  Google Scholar 

  27. Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA . Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008; 57: 907–912.

    Article  CAS  Google Scholar 

  28. Cameron L, Webster RB, Strempel JM, Kiesler P, Kabesch M, Ramachandran H et al. Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C>T, a polymorphism associated with allergic inflammation. J Immunol 2006; 177: 8633–8642.

    Article  CAS  Google Scholar 

  29. Demaria S, Bhardwaj N, McBride WH, Formenti SC . Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63: 655–666.

    Article  Google Scholar 

  30. Ménard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F . Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57: 1579–1587.

    Article  Google Scholar 

  31. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122–1129.

    Article  CAS  Google Scholar 

  32. Ho-Pun-Cheung A, Assenat E, Thezenas S, Bibeau F, Rouanet P, Azria D et al. Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1094–1101.

    Article  CAS  Google Scholar 

  33. Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol 2009; 27: 1592–1599.

    Article  CAS  Google Scholar 

  34. Wu X, Gu J, Wu T, Swisher SG, Liao Z, Correa AM et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789–3798.

    Article  CAS  Google Scholar 

  35. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 281–288.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by Merck Santé and the ANRT (Association Nationale de la Recherche Technique).

Author information

Authors and Affiliations

  1. Department of Biology, Val d'Aurelle Cancer Institute, Montpellier, France

    A Ho-Pun-Cheung & E Lopez-Crapez

  2. INSERM U896, Val d’Aurelle Cancer Institute, Montpellier, France

    A Ho-Pun-Cheung, D Azria & M Ychou

  3. Merck Serono, Lyon, France

    A Ho-Pun-Cheung & D Cellier

  4. Department of Medical and Digestive Oncology, Val d’Aurelle Cancer Institute, Montpellier, France

    E Assenat, P Senesse & M Ychou

  5. Department of Biostatistics, Val d’Aurelle Cancer Institute, Montpellier, France

    C Bascoul-Mollevi & S Thezenas

  6. Department of Pathology, Val d’Aurelle Cancer Institute, Montpellier, France

    F Bibeau & F Boissière-Michot

  7. Department of Radiation Oncology, Val d’Aurelle Cancer Institute, Montpellier, France

    D Azria

  8. Department of Surgical Oncology, Val d’Aurelle Cancer Institute, Montpellier, France

    P Rouanet

Authors
  1. A Ho-Pun-Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Assenat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Bascoul-Mollevi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Bibeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Boissière-Michot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Thezenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Cellier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Azria
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Rouanet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Senesse
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Ychou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Lopez-Crapez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Lopez-Crapez.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ho-Pun-Cheung, A., Assenat, E., Bascoul-Mollevi, C. et al. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Pharmacogenomics J 11, 437–443 (2011). https://doi.org/10.1038/tpj.2010.62

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.62

Keywords

This article is cited by

Search

Advanced search

Quick links